NCT01231529 - GSK1349572 Hepatic Impairment Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 19, 2010

Primary Completion Date

June 4, 2011

Study Completion Date

June 4, 2011

Conditions

Healthy SubjectsHepatic ImpairmentInfection, Human Immunodeficiency VirusHIV Infections

Interventions

DRUG

GSK1349572

All subjects will receive a single dose of GSK1349572 50 mg. GSK1349572 is an experimental drug in the integrase inhibitor class being developed for the treatment of HIV infection. GSK1349572 is not approved by the FDA.

Trial Locations (1)

55404

GSK Investigational Site, Minneapolis